publity AG

  • WKN: 697250
  • ISIN: DE0006972508
  • Land: Deutschland

Nachricht vom 19.10.2021 | 10:50

publity AG plans addition of new majority shareholder in its subsidiary PREOS Global Office Real Estate & Technology AG and terminates plans to sell its PREOS stake

publity AG / Key word(s): Real Estate/Investment
publity AG plans addition of new majority shareholder in its subsidiary PREOS Global Office Real Estate & Technology AG and terminates plans to sell its PREOS stake

19-Oct-2021 / 10:50 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Publication of inside information pursuant to Article 17 of Regulation (EU) No 596/2014

publity AG plans addition of new majority shareholder in its subsidiary PREOS Global Office Real Estate & Technology AG and terminates plans to sell its PREOS stake

Frankfurt/Main, 19 October 2021 - publity AG (Scale, ISIN DE0006972508, "publity") plans to join PREOS as a new majority shareholder together with the Group's subsidiary PREOS Global Office Real Estate & Technology AG ("PREOS"), a Luxembourg-based investment company with its own investor consortium of established European insurance companies managed by a general partner. In this context, the PREOS subsidiary GORE German Office Real Estate AG ("GORE") is to be simultaneously restructured and sold by PREOS. For this purpose, a letter of intent with the participation of PREOS and GORE. In the event of a positive conclusion of the due diligence reviews, a basic agreement on the implementation of the transaction will be signed. The letter of intent essentially provides for the following steps:

In a first step, a portfolio of Luxembourg real estate project developments consisting of an investment holding and a debt fund with a market value expected to exceed EUR 1 billion is to be contributed to GORE through a capital increase in kind against the issuance of new GORE shares. The value to be applied to the GORE shares is to be determined on the basis of the stock exchange price and on the basis of a company valuation and is expected to be within a range of EUR 2.00 to EUR 3.00 per GORE share. This will result in a value adjustment requirement for PREOS with regard to the approx. 23 million GORE shares valued at EUR 4.00 in the annual financial statements per 31 December 2020.

In a second step, the newly created GORE shares are to be contributed to PREOS also in the context of a capital increase against contributions in kind against the issue of new PREOS shares. The value to be applied to the PREOS shares shall also be determined in this case on the basis of the stock exchange price and on the basis of a company valuation. It is expected to be in a range of EUR 4.50 to EUR 5.50 per PREOS share. As a result, the new investor acquires a majority of more than 50% of the share capital of PREOS.

The required Shareholders' Meeting resolutions for the first two steps are planned for the beginning of 2022.

The GORE shares held by PREOS following these two transaction steps are to be reallocated to investors in a third step. For this purpose, GORE is to sell its German real estate portfolio and focus exclusively on the acquisition of commercial real estate projects located in Luxembourg.

The revenues accruing to PREOS from the re-placement of the GORE shares are to be used as equity shares for the further expansion of the PREOS real estate portfolio with a focus on premium properties in the commercial real estate market in Germany and, in a further step, in other European financial metropolises. Due to this inflow of funds, the PREOS real estate portfolio is expected to grow by a total market value on properties of at least EUR 3 billion by the end of 2023. At the same time, two supervisory board positions and the executive board are to be newly filled.

As the parent company of PREOS and as its asset manager, publity expects a significant increase in the managed portfolio in the medium term. This also results in a medium-term increase in turnover.

Against the background of this planned transaction, publity has abandoned its intention to sell its stake in PREOS and will no longer pursue the talks with the Asian conglomerate on the acquisition of a PREOS stake (see ad hoc notification dated 25 January 2021).

Furthermore, publity does not intend to resume the public offerings of PREOS tokens and PREOS shares that have been terminated for the time being (see ad hoc notification of 26 February 2021).


Information and Explanation of the Issuer to this News:

Press Contact:

Financial Press and Investor Relations:
edicto GmbH
Axel Mühlhaus/ Svenja Liebig
Phone: +49 69 905505-52


About publity
publity AG ('publity') is an asset manager and investor specialised in office real estate in Germany. The company covers the core of the value chain from the acquisition to the development and the sale of real estate. With over 1,100 transactions in the past seven years, publity is one of the most active players in the real estate market. publity is characterized by a sustainable network in the real estate industry and in the Work-Out departments of financial institutions. With very good access to investment funds, publity handles transactions rapidly with a highly efficient process and proven partners. On a case-by-case basis, publity participates as co-investor in joint venture transactions to a limited extent. The shares of publity AG (ISIN DE0006972508) are traded on the Scale segment of Deutsche Börse.

19-Oct-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021